Ignite Creation Date:
2025-12-24 @ 3:37 PM
Ignite Modification Date:
2026-01-05 @ 5:41 PM
Study NCT ID:
NCT01238692
Status:
COMPLETED
Last Update Posted:
2023-03-24
First Post:
2010-11-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)
Sponsor:
Sarit Assouline
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2010-11
Start Date Type:
None
Primary Completion Date:
2016-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-12
Completion Date Type:
ACTUAL
First Submit Date:
2010-11-10
First Submit QC Date:
None
Study First Post Date:
2010-11-11
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-03-23
Last Update Post Date:
2023-03-24
Last Update Post Date Type:
ACTUAL